Clinical Trials Browser

Phase 1/2 × Active not recruiting × camrelizumab × Clear all

NCT05176002 2025-11-19

Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

Phase 1/2 Active not recruiting

Gastrointestinal

Esophageal Neoplasms

NCT04706598 2024-07-12

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms